These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 21499766

  • 1. Common toxicities of mammalian target of rapamycin inhibitors.
    Soefje SA, Karnad A, Brenner AJ.
    Target Oncol; 2011 Jun; 6(2):125-9. PubMed ID: 21499766
    [Abstract] [Full Text] [Related]

  • 2. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB, Bivona C, Medina PJ.
    Am J Health Syst Pharm; 2010 Dec 15; 67(24):2095-106. PubMed ID: 21116000
    [Abstract] [Full Text] [Related]

  • 3. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
    Lo Muzio L, Arena C, Troiano G, Villa A.
    Oral Dis; 2018 Mar 15; 24(1-2):144-171. PubMed ID: 29480626
    [Abstract] [Full Text] [Related]

  • 4. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E, Zelnak A, O'Regan R.
    Breast Cancer Res Treat; 2013 Aug 15; 140(3):453-62. PubMed ID: 23907751
    [Abstract] [Full Text] [Related]

  • 5. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J, Tian D.
    Curr Med Res Opin; 2014 Jan 15; 30(1):67-74. PubMed ID: 24028709
    [Abstract] [Full Text] [Related]

  • 6. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ, Paul E.
    J Clin Pharmacol; 2015 Apr 15; 55(4):368-76. PubMed ID: 25402866
    [Abstract] [Full Text] [Related]

  • 7. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M, Elaidi R, Brizard M, Fouque J, Takouchop C, Sabatier B, Oudard S, Medioni J.
    BMC Cancer; 2017 Jan 06; 17(1):27. PubMed ID: 28061764
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R, Lacouture M, Wu S.
    Acta Oncol; 2015 Jan 06; 54(1):124-32. PubMed ID: 24914484
    [Abstract] [Full Text] [Related]

  • 10. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
    Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD.
    Ann Oncol; 2013 Aug 06; 24(8):2092-7. PubMed ID: 23658373
    [Abstract] [Full Text] [Related]

  • 11. Adverse events associated with mTOR inhibitors.
    Pallet N, Legendre C.
    Expert Opin Drug Saf; 2013 Mar 06; 12(2):177-86. PubMed ID: 23252795
    [Abstract] [Full Text] [Related]

  • 12. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
    Qi WX, Huang YJ, Yao Y, Shen Z, Min DL.
    PLoS One; 2013 Mar 06; 8(6):e65166. PubMed ID: 23785409
    [Abstract] [Full Text] [Related]

  • 13. mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
    Kurdi A, Martinet W, De Meyer GRY.
    Transplantation; 2018 Feb 06; 102(2S Suppl 1):S44-S46. PubMed ID: 28230638
    [Abstract] [Full Text] [Related]

  • 14. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
    Rodriguez-Pascual J, Cheng E, Maroto P, Duran I.
    Anticancer Drugs; 2010 Jun 06; 21(5):478-86. PubMed ID: 20401967
    [Abstract] [Full Text] [Related]

  • 15. Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors.
    Zhang Y, Yan H, Xu Z, Yang B, Luo P, He Q.
    Expert Opin Drug Metab Toxicol; 2019 Sep 06; 15(9):767-774. PubMed ID: 31478386
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.
    Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, Feldman DR, Konner JA, Reidy-Lagunes D, Myskowski PL, Lacouture ME.
    Cancer; 2012 Oct 15; 118(20):5078-83. PubMed ID: 22437824
    [Abstract] [Full Text] [Related]

  • 18. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct 15; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 19. Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
    Bourgier C, Massard C, Moldovan C, Soria JC, Deutsch E.
    Ann Oncol; 2011 Feb 15; 22(2):485-6. PubMed ID: 21278224
    [No Abstract] [Full Text] [Related]

  • 20. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
    Peuvrel L, Quéreux G, Brocard A, Saint-Jean M, Dréno B.
    Dermatology; 2012 Feb 15; 224(3):204-8. PubMed ID: 22614575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.